Pages that link to "Q43956053"

The following pages link to Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy (Q43956053):

Displaying 50 items.

• Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions (Q26774355) ‎ (← links)
• Antitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubbles (Q28484485) ‎ (← links)
• Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization. (Q30366774) ‎ (← links)
• The development of combretastatin A4 phosphate as a vascular targeting agent (Q33185300) ‎ (← links)
• A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer (Q33389126) ‎ (← links)
• Antivascular therapy for epithelial ovarian cancer (Q33583598) ‎ (← links)
• Targeted therapies in epithelial ovarian cancer (Q33606699) ‎ (← links)
• DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization (Q33773787) ‎ (← links)
• The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents (Q34122191) ‎ (← links)
• The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts (Q34303312) ‎ (← links)
• Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503 (Q34491366) ‎ (← links)
• The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors (Q34768492) ‎ (← links)
• Design, Synthesis and Cytotoxicity Evaluationof New 1,2-diaryl-4, 5, 6, 7-Tetrahydro-1H-benzo[d] Imidazolesas Tubulin Inhibitors (Q34777723) ‎ (← links)
• An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate. (Q34954063) ‎ (← links)
• Potential of DMXAA combination therapy for solid tumors (Q34969287) ‎ (← links)
• Antivascular therapy of cancer: DMXAA. (Q35080280) ‎ (← links)
• Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts (Q35082693) ‎ (← links)
• Drugs that target dynamic microtubules: a new molecular perspective (Q35163252) ‎ (← links)
• Tumor angiogenesis as a target for dietary cancer prevention (Q35250910) ‎ (← links)
• Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI. (Q35402062) ‎ (← links)
• Vascular targeting agents (Q35642613) ‎ (← links)
• Targeting the tumor vasculature: a strategy to improve radiation therapy (Q35728789) ‎ (← links)
• Characterizing the tumor response to treatment with combretastatin A4 phosphate (Q35793182) ‎ (← links)
• Vascular-targeting therapies for treatment of malignant disease. (Q35805639) ‎ (← links)
• Combretastatin A4 phosphate: background and current clinical status (Q35871932) ‎ (← links)
• Disrupting tumour blood vessels (Q36146900) ‎ (← links)
• Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy (Q36421581) ‎ (← links)
• Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer (Q36506995) ‎ (← links)
• Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. (Q36611295) ‎ (← links)
• Temporal aspects of the action of ASA404 (vadimezan; DMXAA) (Q36641876) ‎ (← links)
• ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. (Q36696611) ‎ (← links)
• Tumour targeting by microtubule-depolymerizing vascular disrupting agents (Q37008845) ‎ (← links)
• Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma (Q37157832) ‎ (← links)
• Vascular priming enhances chemotherapeutic efficacy against head and neck cancer (Q37169566) ‎ (← links)
• Vascular targeted therapies in oncology (Q37254370) ‎ (← links)
• Microtubule dynamics as a target in oncology (Q37360708) ‎ (← links)
• Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). (Q37458557) ‎ (← links)
• Recent advances in tumor vasculature targeting using liposomal drug delivery systems. (Q37603355) ‎ (← links)
• Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. (Q37694429) ‎ (← links)
• Tumor vasculature as target for therapeutic intervention. (Q37800110) ‎ (← links)
• Vascular-disrupting agents in oncology (Q38073812) ‎ (← links)
• An update on the clinical development of drugs to disable tumor vasculature (Q38088732) ‎ (← links)
• Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor. (Q38322817) ‎ (← links)
• Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes. (Q38938545) ‎ (← links)
• Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma (Q40227957) ‎ (← links)
• Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI. (Q43792334) ‎ (← links)
• Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo (Q44412196) ‎ (← links)
• Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. (Q44942124) ‎ (← links)
• Enhanced killing of HepG2 during cryosurgery with Fe3O4-nanoparticle improved intracellular ice formation and cell dehydration (Q47107013) ‎ (← links)
• Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer (Q49909762) ‎ (← links)